• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Overall seroprevalence of SARS-CoV-2 antibodies relatively low in the USA adult and dialysis populations

byVineeth BhogadiandTeddy Guo
November 10, 2020
in Infectious Disease, Nephrology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The standardized seroprevalence of SARS-CoV-2 antibodies in the US population was estimated to be 9.3% with significant regional variation.

2. Higher rates of seropositivity were seen in residents of non-Hispanic Black and Hispanic neighborhoods, as well as neighborhoods in the highest population density quintile.

Evidence Rating Level: 3 (Average)

Study Rundown: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, the causative agent of COVID-19, stimulates a rapid antibody response in both symptomatic and asymptomatic individuals. Given the scale of the pandemic, accurately estimating the seroprevalence of SARS-CoV-2 antibodies in the population is critical to estimate rates of exposure and spread of the virus. However, most studies estimating seroprevalence to date have been restricted to specific hotspots or populations with poor longitudinal follow-up. This cross-sectional study utilized a SARS-CoV-2 spike protein receptor binding domain (S1RBD) total antibody chemiluminescence assay to analyze samples obtained from patients undergoing dialysis across the USA. Overall, standardized seroprevalence of SARS-CoV-2 antibodies in the US population was estimated to be 9.3% with significant regional variation. Regional seroprevalence was lowest in the west and highest in the northeastern states. Other factors associated with higher seroprevalence included race and ethnicity with highest rates in non-Hispanic black and Hispanic patients followed by non-Hispanic white patients having the lowest rates. A major strength of the study comes from the large sample size and sample scheme allowing for estimates of seroprevalence with high precision. However, it is plausible that seroprevalence estimates from the US dialysis population overestimate seroprevalence compared to the general US population. Additionally, there may be an under-representation of patients living in rural areas as dialysis units are more often located in urban centers and public transportation has been less accessible in the current pandemic.

Click to read the study in The Lancet

Relevant Reading: Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

In-Depth [cross-sectional study]: This national, cross-sectional study included 28,503 adults (age ≥18, 57.4% male) receiving dialysis in July 2020 with plasma samples obtained from approximately 1300 dialysis facilities across the USA. Samples were analyzed with a SARS-CoV-2 spike protein receptor binding domain total antibody chemiluminescence assay (100% sensitivity, 99.8% specificity) and data was correlated with age, sex, region, and race and ethnicity information gathered from anonymized electronic health records.

RELATED REPORTS

Empagliflozin use is associated with slower progression of chronic kidney disease

Unvaccinated status increases risk of long COVID symptoms

Slight increase of incidence of myocarditis post-mRNA SARS-CoV-2 vaccination

Overall seroprevalence of SARS-CoV-2 was 8.0% (95% CI 7.7 to 8.4) in the sample population and 9.3% (95% CI 8.8 to 9.9) when standardized to the US adult population. When standardized to the US dialysis population, there was significant regional variance in seroprevalence ranging from 3.5% (95% CI 3.1 to 3.9) in the west to 27.2% (95% CI 25.9 to 28.5) in the northeast. In comparison to the estimated seropositivity rate of 8989 per 100,000 population, the prevalence of nasopharyngeal swab diagnosed cases at the same time was 826 per 100,000 meaning that 9.2% (95% CI 8.7 to 9.8) of seropositive individuals were diagnosed. Likelihood of SARS-CoV-2 seropositivity was lower amongst older individuals (>80 years) versus people aged 45-64 years (odds ratio 0.8, 95% CI 0.7 to 0.9) but did not differ by gender (odds ratio 1.0, 95% CI 0.9 to 1.1) for women versus men. Non-Hispanic black patients had the highest rates of seropositivity in the sample population (14.7%, 95% CI 13.3 to 16.3) followed by Hispanic patients (9%, 95% CI 8.2 to 10.0) and non-Hispanic white patients (4.2%, 95% CI 3.8 to 4.7). Serial sampling of dialysis patients may be a viable way to determine trends in disease prevalence and effectiveness of management strategies as the COVID-19 pandemic continues to evolve.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: coronarvirusdialysisSARS-CoV-2
Previous Post

Association between anticoagulation, bleeding, and subsequent cancer diagnoses

Next Post

#VisualAbstract: Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies for symptomatic hyponatremia

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Cardiology

Slight increase of incidence of myocarditis post-mRNA SARS-CoV-2 vaccination

December 15, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

November 23, 2022
Next Post
#VisualAbstract:Adjuvant radiotherapy does not improve survival following prostatectomy in men with localized or locally advanced prostate cancer

#VisualAbstract: Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies for symptomatic hyponatremia

AAP recommends disaster preparedness measures for children

Children with congenital heart disease exhibit seasonal variation in physical activity

Delays in surgical intervention do not increase odds of appendiceal perforation

Intravenous iron prior to abdominal surgery may reduce risk of readmission

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
  • Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
  • Extracorporeal CPR and conventional CPR similarly improve cardiac arrest survival
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options